New hope for tough brain tumors: experimental drug SYHA1813 faces off against standard care

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Aged \>= 18 years. * 2\. Histologically confirmed WHO grade II/III meningioma (WHO CNS 5th) that is progressive or recurrent. * 3\. Individuals must have received surgery and radiation therapy. * 4\. There is at least one measurable intracranial tumor lesion in the baseline period (RANO-meningioma). * 5\. KPS≥60. * 6\. The expected survival time is \>=3 months. * 7\. The organ function level and related laboratory indicators must meet requirement. * 8\. Agree to use reliable and effective methods of contraception during the study treatment period and for at least 3 months after the last study treatment. Exclusion Criteria: * 1\. Individuals who are known to have severe allergic reaction to the study drug or any other ingredients/excipients in the formulation. * 2\. Meets one of the following conditions: patients with brainstem involvement or extracranial metastasis; patients with severe brain herniation or at risk of brain herniation. * 3\. History of other malignant tumors within 3 years or concurrent active malignant tumors. * 4\. The toxic reactions of previous anti-tumor treatments have not yet recovered to ≤ Grade 1. * 5\. Have used potent inhibitors or inducers of CYP3A4, CYP2C19 or CYP1A2 within the 14 days prior to randomization or are still requiring continued use of such agents. * 6\. Individuals currently receiving warfarin or other oral anticoagulants (excluding those who use low-dose anticoagulants to maintain patency of central venous access or prevent deep vein thrombosis). * 7\. Individuals who are unable to undergo enhanced MRI (such as those with pacemakers, metal dentures, claustrophobia, contrast agent allergies, etc.). * 8\. Individuals with evidence or medical history of bleeding tendency within 2 months prior to randomization. * 9\. Individuals with urine protein ≥ 2+, and 24-hour quantitative urine protein ≥ 1.0 g/24 h upon testing. * 10\. History of acquired immunodeficiency syndrome or HIV antibody positivity in the past; Active hepatitis C; Active hepatitis B. * 11\. Individuals with poorly healing wounds or ulcers, or fractures that require treatment or exhibit poor healing. * 12\. Within 14 days prior to randomization, there were severe chronic or active infections (including tuberculosis infections) that required intravenous injection of antibacterial, antifungal or antiviral therapy. * 13\. Individuals with cardiovascular and cerebrovascular diseases of significant clinical significance. * 14\. Have undergone surgery of major vital organs within 28 days prior to randomization (excluding puncture biopsy). * 15\. Individuals with swallowing difficulties or known medication absorption disorders. * 16\. Pregnant or lactating women. * 17\. Any other conditions that may interfere with the participant's adherence to study procedures, compromise the participant's best interests in participating in the study, or affect study results.